Target intelligence / Profile preview

Muscle hypertonia (None)

Target
None
Molecular classification
Other (clinical syndrome/condition)
01

Overview

Muscle hypertonia describes a clinical condition of excessive muscle tone, commonly caused by damage to motor pathways of the central nervous system[1][3][6][7]. It frequently presents with stiff, difficult-to-move limbs, and may result in increased risk of falls, contractures, and immobilization complications[1][6][7]. The condition may manifest as spasticity (velocity-dependent increased muscle tone and exaggerated reflexes) or rigidity (uniform increased tone regardless of movement) depending on the underlying neurological disorder[2][4][6][8]. Treatments focus on symptom control, primarily using physical therapy, muscle relaxant medications (like baclofen), and injectables (like botulinum toxin), tailored to the individual patient's needs and disease context[5]. Muscle hypertonia itself is not a molecular target for drugs but reflects dysfunction or disease in underlying neural pathways or molecular targets such as GABA_B receptors, alpha motor neurons, or neuromuscular junctions[5].

Other names
HypertoniaIncreased muscle toneStiff muscle toneSpasticityRigidity
02

Mechanism of action

Central nervous system depressants (such as baclofen, which acts as a GABA_B receptor agonist to reduce muscle spindle activity); Chemodenervation (botulinum toxin blocks acetylcholine release at neuromuscular junction); Neurolytic agents (phenol injection produces local nerve block)

03

Biological functions

Muscle contraction regulation (clinical effect; not a direct molecular function)
04

Disease associations

Neurological disorders (stroke, cerebral palsy, traumatic brain injury, multiple sclerosis, Parkinson's disease)
05

Safety considerations

Risk of joint contractures and deformity due to untreated hypertoniaImpaired mobility, increased risk of falls and injurySecondary complications (bone fragility, fractures, sores, pneumonia in severe immobility)Adverse effects of systemic muscle relaxants (e.g., sedation, weakness, hepatotoxicity)
06

Interacting drugs

Baclofen

3 more in the full profile.

Beyond the preview

Go deeper on Muscle hypertonia (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Muscle hypertonia (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call